問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

Kaoshiung Chang Gung Memorial Hospital of the C.G.M.F.

Recruiting

List

555Cases

2026-02-01 - 2034-11-14

Phase III

Not yet recruiting
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
8Sites

Not yet recruiting1Sites

Recruiting7Sites

2026-02-06 - 2032-09-25

Phase III

Not yet recruiting
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
7Sites

Not yet recruiting1Sites

Recruiting6Sites

2026-02-12 - 2033-10-12

Phase III

Not yet recruiting
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
9Sites

Not yet recruiting1Sites

Recruiting8Sites

2026-02-20 - 2031-06-30

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
6Sites

Recruiting6Sites

2026-03-16 - 2029-01-31

Phase III

Not yet recruiting
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
12Sites

Not yet recruiting2Sites

Recruiting10Sites

2026-05-01 - 2031-07-20

Phase II

Not yet recruiting
A Study to Evaluate the Long-term Safety and Efficacy of Long-acting Antibodies as Single Agents and in Combinations in Participants with Inflammatory Bowel Disease

  • Condition/Disease

    Ulcerative Colitis Inflammatory Bowel Diseases Colitis Colitis, Ulcerative

  • Test Drug

    SPY001-001 SPY002-091 SPY003-207

Participate Sites
7Sites

Recruiting6Sites

2026-05-01 - 2029-06-12

Phase III

Not yet recruiting
A double-dummy, double-blind, randomized, active controlled, two-way cross-over study with 12-week treatment duration per period, to evaluate the efficacy and safety of QVM149 (indacaterol acetate / glycopyrronium bromide / mometasone furoate) compared to salmeterol xinafoate/fluticasone propionate in children from 12 years to less than 18 years of age with asthma.

  • Condition/Disease

    Asthma

  • Test Drug

    QVM149（Enerzair® Breezhaler®）

Participate Sites
2Sites

Recruiting2Sites

2026-03-01 - 2029-12-31

Phase III

Active
A Phase 3, Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of KarXT + KarX-EC for the Treatment of Agitation Associated with Alzheimer’s Disease (ADAGIO-3)

  • Condition/Disease

    Alzheimer Disease, Agitation

  • Test Drug

    KarXT/KarX-EC

Participate Sites
5Sites

Recruiting5Sites

2026-05-01 - 2030-01-31

Phase II/III

Not yet recruiting
An Open-Label, Single-arm, Multicenter Phase 2/3 Clinical Trial Evaluating Avatrombopag in Adult Patients with Aplastic Anemia (AA) Refractory to or Ineligible for Immunosuppressive Therapy or with Relapsed AA after Immunosuppressive Therapy

  • Condition/Disease

    Aplastic Anemia

  • Test Drug

    Avatrombopag

Participate Sites
4Sites

Recruiting4Sites

2025-03-01 - 2028-09-01

Phase III

Active
A randomized, double-blind, double-dummy, placebo-controlled, multicenter phase 3 trial was conducted in adult and adolescent patients with moderate to severe hidradenitis suppurativa to evaluate the efficacy, safety, and tolerability of two doses of remibrutinib for 68 weeks (RECHARGE-1).

  • Condition/Disease

    suppurative hidradenitis

  • Test Drug

    LOU064

Participate Sites
3Sites

Recruiting3Sites

1 14 15 16 17 18 56
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB